Compare · CGON vs GILD
CGON vs GILD
Side-by-side comparison of CG Oncology Inc. (CGON) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGON and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $166.72B, about 26.3x CGON ($6.34B).
- Over the past year, CGON is up 168.3% and GILD is up 24.1% - CGON leads by 144.2 points.
- CGON has been more active in the news (10 items in the past 4 weeks vs 7 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 16 for CGON).
- Company
- CG Oncology Inc.
- Gilead Sciences Inc.
- Price
- $71.83+3.32%
- $134.23-1.50%
- Market cap
- $6.34B
- $166.72B
- 1M return
- +19.17%
- +5.49%
- 1Y return
- +168.30%
- +24.06%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 1992
- News (4w)
- 10
- 7
- Recent ratings
- 16
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest CGON
- Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $71,170 worth of shares (1,000 units at $71.17) as part of a pre-agreed trading plan (SEC Form 4)
- Director Mulay James exercised 24,165 shares at a strike of $26.63 and sold $1,816,241 worth of shares (24,165 units at $75.16) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by CG Oncology Inc.
- SEC Form 144 filed by CG Oncology Inc.
- Director Liu Brian Guan-Chyun bought $24,814,454 worth of shares (371,085 units at $66.87) (SEC Form 4)
- Director Post Leonard E exercised 5,000 shares at a strike of $0.60 and sold $350,000 worth of shares (5,000 units at $70.00) as part of a pre-agreed trading plan (SEC Form 4)
- The New War on Cancer: Four Public Companies Helping Lead a Medical Revolution
- SEC Form 144 filed by CG Oncology Inc.
- Director Post Leonard E sold $325,000 worth of shares (5,000 units at $65.00) as part of a pre-agreed trading plan and exercised 5,000 shares at a strike of $0.60 (SEC Form 4)
- SEC Form 144 filed by CG Oncology Inc.
Latest GILD
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention